1. Home
  2. ARE vs UTHR Comparison

ARE vs UTHR Comparison

Compare ARE & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alexandria Real Estate Equities Inc.

ARE

Alexandria Real Estate Equities Inc.

HOLD

Current Price

$45.56

Market Cap

8.8B

Sector

Real Estate

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$489.62

Market Cap

20.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARE
UTHR
Founded
1994
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8B
20.3B
IPO Year
1997
1999

Fundamental Metrics

Financial Performance
Metric
ARE
UTHR
Price
$45.56
$489.62
Analyst Decision
Hold
Buy
Analyst Count
10
12
Target Price
$69.38
$495.08
AVG Volume (30 Days)
2.9M
424.3K
Earning Date
01-26-2026
10-29-2025
Dividend Yield
10.29%
N/A
EPS Growth
N/A
16.08
EPS
N/A
26.38
Revenue
$3,058,395,000.00
$3,128,400,000.00
Revenue This Year
N/A
$13.64
Revenue Next Year
N/A
$5.78
P/E Ratio
N/A
$18.55
Revenue Growth
N/A
13.50
52 Week Low
$45.47
$266.98
52 Week High
$107.19
$492.62

Technical Indicators

Market Signals
Indicator
ARE
UTHR
Relative Strength Index (RSI) 25.29 68.10
Support Level $52.39 $470.13
Resistance Level $54.17 $492.62
Average True Range (ATR) 1.84 10.72
MACD 0.30 -0.53
Stochastic Oscillator 0.06 89.55

Price Performance

Historical Comparison
ARE
UTHR

About ARE Alexandria Real Estate Equities Inc.

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. In addition, it is developing a pipeline of projects that includes new indications and delivery devices for existing products and new products to treat PAH and other conditions.

Share on Social Networks: